Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.14 USD
+0.13 (12.87%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 +0.19 (16.67%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.14 USD
+0.13 (12.87%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 +0.19 (16.67%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Zacks News
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 13.25% and 86.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 14.63% and 72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -17.24% and 17.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of 15.94% and 119.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Strong Buy Stocks for October 17th
by Zacks Equity Research
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Cyclacel Pharmaceuticals, Inc. (CYCC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
by Zacks Equity Research
Wix's (WIX) Q3 performance is likely to have benefited from strong bookings growth and an improvement in the user base. Forex volatility and weakness in global macroeconomic conditions are likely to have acted as headwinds.
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Company News for Apr 21, 2020
by Zacks Equity Research
Companies In The News Are: CYCC, CODX, NBY, EXEL
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Company News for April 11, 2017
by Zacks Equity Research
Companies in the News are: SWFT,KNX,WFM,STRP,T,CYCC